NIH Reporter #5R01AI169462-05

Grant Award for Enteroviral 2C Protein Research and Antiviral Strategy Development

This opportunity involves a grant award from the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, to the University of North Carolina at Chapel Hill for academic research. - Government Buyer: - National Institutes of Health (NIH) - National Institute of Allergy and Infectious Diseases (NIAID) - OEMs and Vendors: - No commercial OEMs or vendors are specified; the recipient is a university. - Products/Services Requested: - Academic research service focused on the enteroviral 2C protein - Study of biological functions and therapeutic targeting of the 2C protein in Enterovirus A71, Coxsackievirus B3, and Enterovirus D68 - No commercial products, part numbers, or quantities are specified - Unique or Notable Requirements: - Research aims to develop broad-spectrum antiviral strategies against non-polio human enteroviruses - Focus on conserved viral protein (2C) relevant to genome replication and virion assembly - Project classified under NAICS code 237110 - Estimated contract value: $747,931 - No commercial procurement; this is a grant for academic research

Description

This project focuses on targeting the enterovirus 2C protein as a therapeutic approach against non-polio human enteroviruses (NPEVs), which pose a significant public health threat, especially to infants and children. The research aims to establish models for the biological functions of the 2C protein, which is conserved across NPEVs and involved in genome replication and virion assembly. The study will include Enterovirus A71, Coxsackievirus B3, and Enterovirus D68 to develop broad-spectrum antiviral strategies. The project is funded by the National Institute of Allergy and Infectious Diseases (NIAID) and conducted by the University of North Carolina at Chapel Hill.

View original listing